Skip to main content
. 2021 Dec 20;14(4):e14608. doi: 10.15252/emmm.202114608

Figure 1. Development of preclinical models from 46 fresh samples.

Figure 1

  1. Flow diagram of sample allocation for molecular profiling (M), primary culture, high‐throughput drug screening (HTS), and patient‐derived xenograft (PDX) drug studies.
  2. Outcome of in vitro expansion in 46 fresh samples.
  3. Outcome of PDX establishment in 46 fresh samples.
  4. Outcome of in vitro and in vivo drug testing attempts in 46 fresh samples.